Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 04/09/18

Research Spotlights

Selected CTEP Accomplishments – February 2018

NCI Launches New Resource for Specimens and Data from Cancer Clinical Trials; Cancer Currents Blog Post Featuring Dr. Jeff Abrams and Grace Mishkin

NIH-funded Study Shows Sorafenib Improves Progression-free Survival for Patients with Rare Sarcomas (NCI Press Release)

Targeted Therapy Larotrectinib Shows Promise in Early Trials, Regardless of Cancer Type

TARGET Study Finds Major Differences between Childhood and Adult AML

Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia

Unique Trial Aims to Decrease Early Deaths in Patients with Rare Leukemia

Prior Cancers Common in Patients Newly Diagnosed with Cancer

Expanding Cancer Clinical Trial Access for Patients with HIV

Extensive Lymph Node Removal Doesn't Improve Survival in Some Women with Early-Stage Breast Cancer

Kids First Pediatric Research Program Moves Forward

Crizotinib Shows Promise for Childhood Cancers

Bringing the Investigational Breast Cancer Drug Endoxifen from Bench to Bedside with NCI Support

Two New Therapies Approved for Acute Myeloid Leukemia

NCI-COG Pediatric MATCH

Extensive Lymph Node Surgery Does Not Increase Survival in Melanoma

Less Chemotherapy May Be Best Choice for Some Patients with Colon Cancer, Study Shows

Midostaurin Approved by FDA for Acute Myeloid Leukemia

Intensive Pre-Stem Cell Transplant Regimen May be Best for Younger Patients with AML, MDS

Collection of Patient-Reported Outcomes Feasible in Cancer Clinical Trials